

FROM  
3<sup>rd</sup> TO 4<sup>th</sup> OCTOBER  
2024

13<sup>th</sup> ANNUAL  
ACUTE  
LEUKEMIA  
MEETING

IN PERSON & VIRTUAL EVENT

DIRECTOR

Dr. Adolfo de la Fuente

*MD Anderson Cancer Center Madrid, Spain*

[www.mdanderson.es/cursoleucemia](http://www.mdanderson.es/cursoleucemia)

## Scientific Committee

**Dr. Gabriela Rodríguez**

*Hospital General Universitario Gregorio Marañón*

**Dr. María Luz Amigo**

*Hospital General Universitario Morales Meseguer, Murcia, Spain*

**Dr. Valentín García-Gutiérrez**

*Hospital Universitario Ramón y Cajal, Madrid, Spain*

**Dr. Guillermo García-Manero**

*MD Anderson Cancer Center, Houston, USA*

**Dr. Mayte Olave**

*Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain*

**Dr. Belén Vidriales**

*Hospital Clínico Universitario de Salamanca, Spain*

**Dr. Mar Tormo**

*Hospital Clínico Universitario de Valencia, Spain*

**Dr. David Valcárcel**

*Hospital valle de Hebron Barcelona. Institute of Oncology,  
Hospital Quirónsalud Barcelona, Spain*

**Dr. Claudio Cerchione**

*IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” - IRST, Meldola, Italy*

**Dr. Naval Daver**

*MD Anderson Cancer Center, Houston, USA*

**Dr. Alessandro Isidori**

*Marche Nord Hospital, Pesaro, Italy*

**Dr. Elias Jabbour**

*MD Anderson Cancer Center, Houston, USA*

## Ambassadors

**Dr. Virginia Abello**

*Centro de tratamiento e investigación sobre Cáncer Luis Carlos Sarmiento Angulo,  
Bogotá, Colombia*

**Dr. Breno Moreno de Gusmão**

*Benecência Portuguesa de São Paulo, São Paulo, Brasil*

**Dr. Marta Rivas**

*Hospital Universitario Austral, Buenos Aires, Argentina*

**Dr. Alejandra Romero**

*Hospital Clínico Regional Dr. Guillermo Grant Benavente, Bío Bío, Chile*

## Evaluation Committee

**Dr. M<sup>a</sup> Luz Amigo Lozano**

*Hospital General Univ. Morales Meseguer, Murcia*

**Dr. Adolfo de la Fuente**

*MD Anderson Cancer Center Madrid*

**Dr. Mayte Olave**

*Hospital Clínico de Zaragoza*

**Dr. Gabriela Rodríguez**

*Hospital General Univ. Gregorio Marañón, Madrid*

**Dr. Mar Tormo**

*Hospital Clínico Universitario de Valencia, Spain*

**Dr. David Valcárcel**

*Hospital Univ. Vall d'Hebron, Institute of Oncology, Barcelona*

**Dr. María Belén Vidriales**

*Hospital Clínico Universitario de Salamanca, Spain*

09:00 - 09:10

**Welcome**

Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*

09:10 - 10:20

**Session 1**

**Myelodysplastic syndromes I**

Chairs:

Dr. David Valcárcel, *Hospital Universitario Vall d'Hebron, Institute of Oncology, Hospital Quirónsalud Barcelona, Spain*

Dr. Guillermo García-Manero, *MD Anderson Cancer Center, Houston, USA*

Dr. Breno Moreno de Gusmão, *Benecência Portuguesa de São Paulo, São Paulo, Brasil*

09:10 - 09:30

**Germline predisposition: Clinical relevance, who to study? Impact on patient management**

Dr. Julia Montoro, *Hospital Universitario Vall d'Hebron, Barcelona, Spain*

09:30 - 09:50

**Low- risk MDS, looking to the future**

Dr. Ana Alfonso, *Clínica Universidad de Navarra, Pamplona, Spain*

09:50 - 10:10

**Targeted Approaches in MDS**

Dr. Lionel Adès, *Hôpital Saint-Louis, Paris, France*

10:10 - 10:20

**Discussion**

10:20 - 10:50

**Meet the Expert 1**

**Management of myelofibrosis in 2024**

Chairs:

Dr. María Luz Amigo, *Hospital General Universitario Morales Meseguer, Murcia, Spain*

Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*

Dr. Virginia Abello, *Centro de tratamiento e investigación sobre Cáncer Luis Carlos Sarmiento Angulo, Bogotá, Colombia*

10:20 - 10:40

Dr. Valentín García-Gutiérrez, *Hospital Universitario Ramón y Cajal, Madrid, Spain*

10:40 - 10:50

**Discussion**

10:50 - 11:20

**Coffee break**

11:20 - 12:35

## Session 2

### Immunotherapy

*Chairs:* Dr. Gabriela Rodríguez, *Hospital General Universitario Gregorio Marañón, Madrid, Spain*  
Dr. Valentín García-Gutiérrez, *Hospital Universitario Ramón y Cajal, Madrid, Spain*  
Dr. Marta Rivas, *Hospital Universitario Austral, Buenos Aires, Argentina*

11:20 - 11:40

### Immunotherapy a history of failures

Dr. Alessandro Isidori, *Marche Nord Hospital, Pesaro, Italy*

11:40 - 12:00

### Immunotherapy a history of successes

Dr. Antonio Curti, *Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola, Bologna, Italy*

12:00 - 12:20

### Targeting CD123 and CD33 in AML: Antibodies and cell therapy approaches

Dr. Naval Daver, *MD Anderson Cancer Center, Houston, USA*

12:20 - 12:35

### Discussion

12:35 - 14:10

## Session 3

### AML redefining risks and opportunities

*Chairs:* Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*  
Dr. Mar Tormo, *Hospital Clínico Universitario de Valencia, Spain*  
Dr. Ángela Figuera, *Hospital de La Princesa, Madrid, Spain*

12:35 - 12:55

### Redefining fit and unfit. Criteria

Dr. Alessandro Isidori, *Marche Nord Hospital, Pesaro, Italy*

12:55 - 13:15

### Transplantation in seniors over 70 years

Dr. María Queralta Salas, *Hospital Clínic de Barcelona, Spain*

13:15 - 13:35

### Tips and tricks oral azacitidine as maintenance in AML

Dr. María Teresa Voso, *University of Rome Tor Vergata, Roma, Italy*

13:35 - 13:55

### Update on antibiotherapy and antifungals in/for the haematological patient

Dr. Rafael de la Cámara, *Hospital Universitario de La Princesa, Madrid, Spain*

13:55 - 14:10

### Discussion

14:10 - 15:10

### Lunch

14:10 - 14:40

## Meet the Expert 2

### Challenges in the treatment of patients with CLL in 2024

Chair:

Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*

Dr. Breno Moreno de Gusmão, *Benecência Portuguesa de São Paulo, São Paulo, Brasil*

Dr. Virginia Abello, *Centro de tratamiento e investigación sobre Cáncer Luis Carlos Sarmiento Angulo, Bogotá, Colombia*

14:10 - 14:30

Dr. Mayte Olave, *Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain*

14:30 - 14:40

Discussion

15:10 - 16:25

## Session 4

### AML II - Target therapies

Chairs:

Dr. María Belén Vidriales, *Hospital Clínico Universitario de Salamanca, Spain*

Dr. María Luz Amigo, *Hospital General Universitario Morales Meseguer, Murcia, Spain*

Dr. Alejandra Romero, *Hospital Clínico Regional Dr. Guillermo Grant Benavente, Bío Bío, Chile*

15:10 - 15:30

### IDHA inhibitors in AML in 2024 and now what?

Dr. Blanca Boluda, *Hospital Universitario y Politécnico La Fe, Valencia, Spain*

15:30 - 15:50

### Menin inhibitors

Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*

15:50 - 16:10

### Targeting TP 53 where are we now?

Dr. Thomas Cluzeau, *Hospital Center Universitaire de Nice, France*

16:10 - 16:25

Discussion

16:25 - 18:00

**Session 5****Lymphoblastic**

- Chairs:* Dr. Mar Tormo, *Hospital Clínico Universitario de Valencia, Spain*  
Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*  
Dr. Breno Moreno de Gusmão, *Benecência Portuguesa de São Paulo, São Paulo, Brasil*  
Dr. Alejandra Romero, *Hospital Clínico Regional Dr. Guillermo Grant Benavente, Bío Bío, Chile*
- 16:25 - 16:45 **Management of the elderly patient with ALL**  
Dr. Anna Torrent, *Hospital Universitario Germans Trias i Pujol, Barcelona, Spain*
- 16:45 - 17:45 **Discussion: alloSCT for Ph+ ALL to do or not to do?**  
**YES** - Dr. Josep Maria Ribera, *Instituto de Investigación contra la Leucemia Josep Carreras, Barcelona, Spain*  
**NO** - Dr. Elias Jabbour, *MD Anderson Cancer Center, Houston, USA*
- 17:45 - 18:00 **Discussion**
- 18:00 - 18:30 **Coffee break**

18:30 - 20:30

**Session 6****AML I - Targeting FLT3 in AML**

- Chairs:* Dr. Mayte Olave, *Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain*  
Dr. Alessandro Isidori, *Marche Nord Hospital, Pesaro, Italy*  
Dr. Marta Rivas, *Hospital Universitario Austral, Buenos Aires, Argentina*
- 18:30 - 18:50 **AML diagnosis WHO and ICC 2022**  
Dr. Irene Sánchez-Vadillo, *Hospital Universitario La Paz, Madrid, Spain*
- 18:50 - 19:10 **FLT3 AML where do we come from: focus on R/R FLT3 AML**  
Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*
- 19:10 - 19:30 **Optimal approaches to frontline fit FLT3 ITD AML: Which FLT3 inhibitor is the best?**  
Dr. Alexander Perl, *Abramson Cancer Center, Pennsylvania, USA*
- 19:30 - 19:50 **Mechanisms of resistance to FLT3 inhibitors and building novel combinations to overcome resistance**  
Dr. Naval Daver, *MD Anderson Cancer Center, Houston, USA*
- 19:50 - 20:10 **FLT3 inhibitors for FLT3 wild type AML**  
Dr. Blanca Boluda, *Hospital Universitario y Politécnico La Fe, Valencia, Spain*
- 20:10 - 20:30 **Discussion**

08:00 - 09:15

**Session 7****Biology and diagnostics**

Chairs:

Dr. Alessandro Isidori, *Marche Nord Hospital, Pesaro, Italy*Dr. Mayte Olave, *Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain*Dr. Ángela Figuera, *Hospital de La Princesa, Madrid, Spain*

08:00 - 08:20

**Clonal haematopoiesis and leukaemogenesis**Dr. Klaus Metzeler, *Leipzig University, Leipzig, Germany*

08:20 - 08:40

**Genetic alterations in AML and MDS-AR - the same or different?**Dr. Rosa Ayala, *Hospital Universitario 12 de Octubre, Madrid, Spain*

08:40 - 09:00

**Diagnosis and classification of ALL in 2024**Dr. María Luz Amigo, *Hospital General Universitario Morales Meseguer, Murcia, Spain*

09:00 - 09:15

**Discussion**

09:15 - 10:05

**Session 8****Myelodysplastic syndromes II**

Chairs:

Dr. Mar Tormo, *Hospital Clínico Universitario de Valencia, Spain*Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*Dr. Alejandra Romero, *Hospital Clínico Regional Dr. Guillermo Grant Benavente, Bío Bío, Chile*

09:15 - 09:35

**Response criteria in MDS**Dr. David Valcárcel, *Hospital Universitario Vall d'Hebron, Institute of Oncology, Hospital Quirónsalud, Barcelona, Spain*

09:35 - 09:55

**High-risk treatment: Towards total oral therapy**Dr. Guillermo García-Manero, *MD Anderson Cancer Center, Houston, USA*

09:55 - 10:05

**Discussion**

10:05 - 10:35

**Coffee break**



10:35 - 11:50

**Session 9****My day to day life at the AML**

*Chairs:* Dr. Guillermo García-Manero, MD Anderson Cancer Center, Houston, USA  
Dr. María Belén Vidriales, Hospital Clínico Universitario de Salamanca, Spain  
Dr. Marta Rivas, Hospital Universitario Austral, Buenos Aires, Argentina

10:35 - 10:55

**Favourable risk AML. Treatment: transplantation autologous vs CT?**

Dr. Josefina Serrano, Hospital Universitario Reina Sofía, Córdoba, Spain

10:55 - 11:15

**AML with FLT3 mutations - really intermediate risk?**

Dr. Gabriela Rodríguez, Hospital General Universitario Gregorio Marañón, Madrid, Spain

11:15 - 11:35

**What do I offer to my patient in RC1, maintenance or allogeneic transplantation?**

Dr. Mar Tormo, Hospital Clínico Universitario de Valencia, Spain

11:35 - 11:50

**Discussion**

11:50 - 12:55

**WORKSHOP 1****Blastic plasmacytoid dendritic cell neoplasm (BPDCN AML Study and diagnosis)**

*Chairs:* Dr. Elias Jabbour, MD Anderson Cancer Center, Houston, USA  
Dr. Claudio Cerchione, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST, Meldola, Italy  
Dr. Virginia Abello, Centro de tratamiento e investigación sobre Cáncer Luis Carlos Sarmiento Angulo, Bogotá, Colombia  
Dr. Alejandra Romero, Hospital Clínico Regional Dr. Guillermo Grant Benavente, Bío Bío, Chile

11:50 - 12:10

**Challenges in the diagnosis of BPDCN**

Dr. María Belén Vidriales, Hospital Clínico Universitario de Salamanca, Spain

12:10 - 12:30

**Management of the patient with BPDCN**

Dr. Naveen Pemmaraju, MD Anderson Cancer Center, Houston, USA

12:30 - 12:40

**Clinical case**

12:40 - 12:55

**Conclusions**

12:55 - 14:05

**Session 10****The relevance of a precise diagnosis in the mIDH1 AML unfit patient for an optimal frontline treatment**

Chair:

Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*  
Dr. Ángela Figuera, *Hospital de La Princesa, Madrid, Spain*

12:55 - 13:05

**Testing in time: The importance of molecular testing time frames**

Dr. Joaquín Sánchez, *Hospital Universitario Reina Sofía, Córdoba, Spain*

13:05 - 13:15

**How do you manage all the complexities of new treatment choices in the mIDH1 AML patient ineligible for intensive chemotherapy?**

Dr. Pau Montesinos, *Hospital Universitario y Politécnico La Fe, Valencia, Spain*

13:15 - 13:25

**Experience in real world setting with targeted therapies**

Dr. Naval Daver, *MD Anderson Cancer Center, Houston, USA*

13:25 - 13:35

**Clinical case I**

13:35 - 13:45

**Clinical case II**

13:45 - 14:05

**Case based discussion**

14:05-15:05

**Lunch**

15:05 - 16:00

**Session 11****Intensive approach to AML**

Chairs:

Dr. Gabriela Rodríguez, *Hospital General Universitario Gregorio Marañón, Madrid, Spain*  
Dr. Claudio Cerchione, *IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST, Meldola, Italy*  
Dr. Virginia Abello, *Centro de tratamiento e investigación sobre Cáncer Luis Carlos Sarmiento Angulo, Bogotá, Colombia*  
Dr. Alejandra Romero, *Hospital Clínico Regional Dr. Guillermo Grant Benavente, Bío Bío, Chile*

15:05 - 15:25

**High risk AML the big picture and long term follow up**

Dr. Christina Rautenberg, *Essen University Hospital, Stem Cell Transplantation, Essen, Germany*

15:25 - 15:45

**Impact of intensive chemotherapy on the intestinal mucosa**

Dr. Luigina Romani, *University of Perugia, Italy*

15:45 - 16:00

**Discussion**

16:00 - 17:15

**Session 12****AML III- Targeting apoptosis**

*Chairs:* Dr. David Valcárcel, *Hospital Universitario Vall d'Hebron, Institute of Oncology, Hospital Quirónsalud, Barcelona, Spain*

Dr. Naval Daver, *MD Anderson Cancer Center, Houston, USA*

Dr. Ángela Figuera, *Hospital de La Princesa, Madrid, Spain*

16:00 - 16:20

**How to optimize the use of HMA+venetoclax in the unfit patient in healthcare practice**

Dr. Ofir Wolach, *Davidoff Cancer Centre, Petaj Tikva, Israel*

16:20 - 16:40

**Combinations of venetoclax with chemotherapy in AML treatment**

Dr. Rebeca Rodríguez, *Hospital Universitario y Politécnico La Fe, Valencia, Spain*

16:40 - 17:00

**Talk 3**

TBC

17:00 - 17:15

**Discussion**

17:15 - 17:30

**Coffee break**

17:30 - 18:50

**Session 13****MRD in Acute Leukemia**

*Chairs:* Dr. Guillermo García-Manero, *MD Anderson Cancer Center, Houston, USA*

Dr. Alessandro Isidori, *Marche Nord Hospital, Pesaro, Italy*

17:30 - 17:50

**B cell Acute Lymphoblastic Leukemia MRD based algorithm**

Dr. Elias Jabbour, *MD Anderson Cancer Center, Houston, USA*

17:50 - 18:10

**Value of MRD in non-intensively treated AML patients**

Dr. María Belén Vidriales, *Hospital Clínico Universitario de Salamanca, Spain*

18:10 - 18:30

**Management of AML with MRD+ following allogeneic transplantation**

Dr. David Valcárcel, *Hospital Universitario Vall d'Hebron Institute of Oncology, Hospital Quirónsalud, Barcelona, Spain*

18:30 - 18:50

**Discussion**

18:50 - 19:00

**Clinical Cases Award Ceremony**

Friday

4<sup>th</sup>  
OCTOBER  
2024

19:00 - 19:20

### Special session

#### Introducing SOHO

##### The Society of Hematologic Oncology (SOHO)

Dr. Alessandro Isidori, *Marche Nord Hospital, Pesaro, Italy*

Dr. Claudio Cerchione, *IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST, Meldola, Italy*

Dr. Pau Montesinos, *Hospital Universitario y Politécnico La Fe, Valencia, Spain*

Dr. Elias Jabbour, *MD Anderson Cancer Center, Houston, USA*

Dr. Naval Daver, *MD Anderson Cancer Center, Houston, USA*

Dr. Guillermo García-Manero, *MD Anderson Cancer Center, Houston, USA*

Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*

19:20 - 19:30

#### Closing

Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*

Sponsors

PLATINUM

abbvie

 Daichi-Sankyo

**SERVIER**<sup>\*</sup>  
moved by you

GOLD

 Bristol Myers Squibb™

 **MENARINI**  
group

**Stemline**<sup>®</sup>  
A Menarini Group Company

SILVER

 Incyte

 **Jazz** Pharmaceuticals.

 **NOVARTIS**

 Otsuka

 **Pfizer**

BRONZE

**AstraZeneca** 

 **BeiGene**

**CURIS**<sup>®</sup>

**RYVU**  
THERAPEUTICS

COLABORATORS

**AMGEN**<sup>®</sup>

## Organized By

MD Anderson  
~~Cancer Center~~  
Madrid • España

MD Anderson  
~~Cancer Center~~  
Fundación • España

## Accreditation

Credits requested from the Continuing Education Commission  
of Health Professions of the Community of Madrid

## Auspice

With scientific endorsement



Sociedad Española de  
Hematología y Hemoterapia

## Venue

MD Anderson Cancer Center Spain Foundation Auditorium  
C/ Arturo Soria, 270, 28033, Madrid

## Technical Secretary

**doctaforum**

(+34) 91 372 02 03  
e-mail: [cursoleucemia@doctaforum.com](mailto:cursoleucemia@doctaforum.com)  
[www.mdanderson.es/cursoleucemia](http://www.mdanderson.es/cursoleucemia)